Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis

医学 奥克列珠单抗 多发性硬化 美罗华 内科学 梅德林 儿科 肿瘤科 完全响应 中枢神经系统疾病
作者
Øivind Torkildsen,Hilde Kjelgaard Brustad,Einar August Høgestøl,Karl Bjørnar Alstadhaug,Alok Bhan,Heidi Øyen Flemmen,Andrea Habbestad,Rune A.A. Høglund,Marissa LeBlanc,Peter Lopen,Åslaug Rudjord Lorentzen,Åse Hagen Morsund,Andreas Lossius,Rigmor Lundby,Gro O. Nygaard,Brit Ellen Rød,Cecilia Smith Simonsen,Linn Steffensen,Hilde Torgauten,Fredrik Piehl
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:395 (1): 44-53 被引量:1
标识
DOI:10.1056/nejmoa2600993
摘要

BACKGROUND: Anti-CD20 monoclonal antibodies are effective for relapsing multiple sclerosis. However, data from head-to-head trials are lacking. METHODS: In this phase 3, multicenter, double-blind, noninferiority trial, we randomly assigned adults with newly diagnosed relapsing multiple sclerosis and recent disease activity in a 3:2 ratio to receive rituximab or ocrelizumab every 6 months for 24 months. The primary end point was the absence of new or enlarging lesions on T2-weighted magnetic resonance imaging (MRI) from month 6 to month 24. Noninferiority was defined as a lower limit of the 95% confidence interval for the risk difference (rituximab minus ocrelizumab) of greater than or equal to -10 percentage points. Secondary end points included efficacy and safety. RESULTS: A total of 218 participants underwent randomization; 216 received treatment (132 assigned to the rituximab group and 84 assigned to the ocrelizumab group). Between months 6 and 24, the estimated probability of having no new or enlarging lesions detected on T2-weighted MRI was 92.2% with rituximab and 94.8% with ocrelizumab, corresponding to a risk difference of -2.6 percentage points (95% confidence interval, -9.4 to 4.3), which met the prespecified noninferiority criterion. Relapse rates, disability outcomes, and cognitive-performance profiles appeared to be similar in the two groups. Infections were more common in the rituximab group than in the ocrelizumab group (in 82% vs. 69% of participants), although the percentage of participants with serious adverse events was similar in the two groups (8% and 7%, respectively). CONCLUSIONS: In participants with newly diagnosed relapsing multiple sclerosis and recent disease activity, rituximab was noninferior to ocrelizumab in suppressing disease activity as detected by MRI from 6 to 24 months, with a similar incidence of serious adverse events. (Funded by the Research Council of Norway and others; OVERLORD-MS ClinicalTrials.gov number, NCT04578639; EudraCT number, 2020-001205-23; EU Clinical Trials Register number, 2024-510716-71-00.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
爆米花的应助被Vincent采纳,获得10
6秒前
10秒前
HAPPY完成签到,获得积分10
11秒前
桐桐的应助被Vincent采纳,获得10
12秒前
keleboys完成签到 ,获得积分10
14秒前
HMZ完成签到 ,获得积分10
16秒前
17秒前
HU完成签到 ,获得积分10
19秒前
20秒前
24秒前
小尾巴完成签到 ,获得积分10
27秒前
章鱼行者完成签到,获得积分10
27秒前
鲁文杰发布了新的文献求助10
28秒前
Maestro_S的应助被Vincent采纳,获得10
30秒前
31秒前
万能图书馆的应助被Vincent采纳,获得10
37秒前
37秒前
水静完成签到,获得积分10
38秒前
川川完成签到 ,获得积分10
42秒前
43秒前
科研通AI6.4的应助被Vincent采纳,获得10
43秒前
44秒前
标致访旋完成签到,获得积分10
45秒前
烂漫墨镜完成签到 ,获得积分10
48秒前
20230054发布了新的文献求助10
50秒前
50秒前
隐形曼青的应助被Vincent采纳,获得10
52秒前
鲁文杰完成签到,获得积分10
55秒前
55秒前
整齐百褶裙完成签到 ,获得积分10
1分钟前
Changhiwi完成签到 ,获得积分10
1分钟前
李健的小迷弟的应助被Vincent采纳,获得10
1分钟前
1分钟前
彳系禾完成签到 ,获得积分10
1分钟前
Jzhaoc580完成签到 ,获得积分10
1分钟前
冷艳凡灵完成签到,获得积分10
1分钟前
花果茶百道完成签到 ,获得积分10
1分钟前
1分钟前
一定长完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190366
求助须知:如何正确求助?哪些是违规求助? 9577437
关于积分的说明 21852521
捐赠科研通 7788988
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560144
邀请新用户注册赠送积分活动 2482995